Efficacy and Safety of Darolutamide Combined With Docetaxel and ADT as Neoadjuvant Therapy for Locally Advanced Prostate Cancer.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Darolutamide
Related studies linked through entity extraction aliases.
A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)
- Status
- RECRUITING
- Phase
- PHASE3
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
QLC5508 in Advanced Solid Tumors:: C-QTc, Pharmacokinetics (PK) Comparisons and Drug-drug Interaction
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Prostate Androgen Response Investigation Using a Stratification BIOmarker; Predicting Prostate Cancer Downstaging by Neoadjuvant Darolutamide With PCAI ImmunoScore
- Status
- RECRUITING
- Phase
- PHASE2
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Status
- RECRUITING
- Phase
- PHASE3
An Observational Study Conducted in China to Evaluate the Efficacy and Safety of Darolutamide in Combination With Androgen Deprivation Therapy (ADT) for Men With Non-metastatic Prostate Cancer That Progressed Following Prior Bicalutamide + ADT Treatment
- Status
- RECRUITING
- Phase
- N/A
Darolutamide ± ADT as Neoadjuvant Therapy in High-Risk/Very High-Risk Localized Prostate Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.
- Status
- RECRUITING
- Phase
- PHASE2
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
- Status
- COMPLETED
- Phase
- N/A
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics
- Status
- RECRUITING
- Phase
- N/A
A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Status
- RECRUITING
- Phase
- PHASE1
TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response
- Status
- RECRUITING
- Phase
- PHASE2
Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC
- Status
- RECRUITING
- Phase
- PHASE2
Observational Study of the Effectiveness of Funded Drugs for Genitourinary Tumors.
- Status
- RECRUITING
- Phase
- N/A
Evaluating Treatment Outcomes Using Darolutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE4
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
- Status
- RECRUITING
- Phase
- PHASE1